Evaluating the Impact of Alpha Ketoglutarate (AKG), a Geroprotector, in Reducing Morbidity and Improving Patient-Centred Outcomes After Coronary Artery Bypass Grafting Surgery in Resilient and Poorly-Resilient Patients: A Double-Blind Placebo-Controlled Clinical Trial

What this Trial Is About

Coronary artery bypass grafting surgery (CABG) is a common major surgery performed on older patients, involving significant surgical stress and immune responses. This stress can trigger inflammation and systemic effects, sometimes leading to complications like multiple organ dysfunction. Aging also changes immune function, causing increased inflammation and reduced ability to respond to stress, which may affect recovery from surgery. This study evaluates alpha-ketoglutarate (AKG), a dietary supplement thought to protect against aging-related immune changes and improve surgical resilience in patients undergoing CABG. Participants will be randomly assigned to receive either AKG tablets or placebo tablets once daily. The trial is double-blind and placebo-controlled, assessing the impact of AKG on inflammation and recovery after surgery. Participants will be monitored from surgery through 90 days afterward, with assessments including immune and inflammatory markers, muscle mass and strength, infection rates, frailty, pain, disability, quality of life, fatigue, depression, and patient satisfaction. Researchers will also track hospital resource use and long-term outcomes. The primary measurement is a combined assessment of systemic inflammatory response syndrome and organ dysfunction within 90 days after surgery.

Alpha Ketoglutarate Enhances Geroprotection In Surgery (AEGIS)